Biological E. Limited (BE) expects to roll out its COVID-19 vaccine Corbevax by the end of November even as the city-based company prepares 100 million doses for release, said Mahima Datla, managing director, BE. on Monday. Speaking to reporters on the sidelines of signing a financing agreement with the US International Development Finance Corporation (DFC), she said that the manufactured doses are currently being sent to Central Drug Laboratory (CDL), Kasauli in Himachal Pradesh for regulatory testing.

“Cobevax is in phase 3 trials. We will likely have completed all the studies by the end of November which is when we expect licensing (from the drug regulator). Licensing for children should follow after one month. Studies in children are also underway.”

The Biological E coronavirus vaccine, Corbevax, is an RBD subtype vaccine and is currently undergoing Phase 2/3 clinical trials in adults.

She added that the Phase III trials will be a comparative study of already licensed vaccines, although the study in children is not a comparative study. “We are providing potions to Kasauli for release. So I hope that on launch day our vision has always been to get around ten crore potions a day. That might happen in November as soon as we get the license,” she said.

In terms of COVID-19 vaccine manufacturing capabilities, she said BE currently has the capacity to make 1 billion doses of Corbevax annually, and 600 doses of the Johnson & Johnson vaccine. Biological E Ltd previously said it had entered into an agreement with Janssen Pharmaceutica NV, part of major pharmaceutical company Johnson & Johnson, to establish and enhance production capabilities to manufacture the latest COVID-19 vaccine.

Meanwhile, DFC Chief Operating Officer David Marshik and Mahima Datla today revealed the expansion of the Biological E vaccines manufacturing facility. “DFC’s partnership with Biological E will support the ability to produce more than one billion vaccine doses by the end of 2022 for India and the countries,” Marshik said in a press release. developing around the world.

“We are pleased with the financial support from the US government, especially the DFC, which was announced at the quadripartite summit in March 2021. This investment will not only help us increase our ability to produce more COVID-19 vaccines, but will also help the world community that has been struggling relentlessly against the spread of the COVID-19 pandemic.”

Read all the latest news, breaking news and coronavirus news here. Follow us Facebook social networking siteAnd Twitter And cable.

Source link

By admin

Leave a Reply

Your email address will not be published. Required fields are marked *